---
id: RA-001
title: "Building Trust Across the Pharmaceutical Supply Chain"
subtitle: "A Reference Architecture for End-to-End Traceability"
author: "A. S. Tomar"
author_role: "KryoNex Research & Engineering Team"
status: working-draft
document_version: 0.4
publish_date: ""
last_updated: "2026-07-24"
tags:
  - pharmaceutical-traceability
  - supply-chain
  - GS1-EPCIS
  - serialization
  - IoT
  - digital-trust
---
# RA-001 Changelog

All notable research, architecture, evidence, and publication-state changes to
RA-001 are recorded here.

RA-001 follows research-document versioning. A working-draft version does not
indicate production validation or regulatory approval.

---

## [0.4] — 2026-07-24

### Research

- Established the current-state analysis of pharmaceutical product
  identification, serialization, aggregation, traceability-event exchange,
  enterprise systems, regulatory ecosystems, and environmental observations.
- Separated U.S. DSCSA, European medicines-verification, and Indian
  domestic/export contexts rather than treating them as one global
  traceability model.
- Established claim-level evidence tracking through
  `sources/evidence-register.md`.
- Distinguished standards capability, regulatory requirements, industry
  implementation patterns, peer-reviewed research, and KryoNex Research
  architectural synthesis.

### Architecture

- Established F01 — Contemporary Pharmaceutical Supply Chain as the physical
  reference model.
- Developed F02 — Current Pharmaceutical Traceability Landscape as the
  current-state digital and organizational systems model.
- Developed F03 — Trust & Visibility Boundaries as the conceptual assurance
  model.
- Developed F04 — Logical Assurance Architecture for Cross-Organizational
  Pharmaceutical Traceability as the vendor-neutral synthesis of F01–F03.
- Organized F04 into six logical layers: Physical Pharmaceutical Supply Chain,
  Identification & Observation, Authoritative Operational Systems, Traceability
  Semantics & Exchange, Boundary Assurance Capabilities, and Regulatory &
  Partner Ecosystems.
- Defined Evidence Protection and Trust & Lifecycle Governance as cross-cutting
  architectural concerns.
- Established that event integrity does not establish physical truth,
  credential verification does not itself constitute transaction
  authorization, device identity does not establish calibration, and
  immutability does not establish correctness.
- Treated distributed/shared-ledger mechanisms as conditional candidates to be
  evaluated against governance, privacy, latency, complexity, and the need for
  independently governed shared state.
- Integrated assurance outcomes with existing exception, reconciliation,
  investigation, quarantine, and other applicable operational processes rather
  than assuming that every boundary evaluation produces a successful
  verification outcome.
- Established the principle that an assurance boundary does not itself
  constitute a control failure.
- Defined four distinct assurance dimensions — Product Identity, Event
  Integrity, Organizational Authority, and Observation Correlation — and
  carried them forward from F03 into the F04 logical architecture.
- Preserved authoritative regulatory and enterprise systems rather than
  assuming replacement by a new platform.
- Maintained blockchain and distributed-ledger mechanisms as optional
  architectural candidates rather than foundational requirements.

### Figures

- Added F01 physical supply-chain reference figure.
- Added F02 current traceability landscape figure.
- Added F03 trust and visibility boundaries figure.
- Added F04 logical assurance architecture figure.
- Completed the F01–F04 architecture-figure sequence for the v0.4 working
  draft.
- Retained figure-version review as part of the final publication freeze.

### Editorial

- Adopted vendor-neutral and research-oriented terminology.
- Separated physical-world evidence from digital assertions.
- Removed unsupported universal performance and adoption claims.
- Added explicit limitations and production-validation boundaries.
- Established architectural provenance for KryoNex Research synthesis.

### Publication Status

RA-001 remains **Version 0.4 — Working Draft / Under Technical Review**.

The F01–F04 architecture sequence is complete for the v0.4 working draft.

Architecture completion does not constitute publication approval. Regulatory
claims, standards references, evidence mappings, citations, terminology,
cross-figure consistency, and the complete publication remain subject to final
technical and editorial verification.

The next milestone is publication-level technical and evidence verification of
the complete RA-001 artifact.

No v1.0 publication claim is made by this release.
